PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
402.37%
G&A growth above 1.5x CRVO's 37.03%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Similar other expenses growth to CRVO's 100.00%. Walter Schloss would investigate industry patterns.
547.73%
Operating expenses growth above 1.5x CRVO's 251.41%. Michael Burry would check for inefficiency.
547.73%
Total costs growth above 1.5x CRVO's 15.98%. Michael Burry would check for inefficiency.
3.95%
Interest expense change of 3.95% while CRVO maintains costs. Bruce Berkowitz would investigate control.
-96.03%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-2633.53%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-468.26%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
6409.86%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
-429.59%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-75.15%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-263.73%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-197.18%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-197.18%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
22.83%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
22.83%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.